Real-world serplulimab plus chemotherapy for extensive-stage small cell lung cancer in China: an external validation of ASTRUM-005 trial.
Real-world outcomes confirm an immunotherapy combination works as expected for small cell lung cancer across diverse patient populations.
Real-world serplulimab+chemotherapy for ES-SCLC (n=635) confirms median OS 17.2 months and ORR 69%, consistent with the ASTRUM-005 trial via MAIC analysis; poor PS and liver metastases predict worse outcomes. This record was retained from the prior triage attempt for PubMed pipeline handoff.
What the study was
- Study design
- nationwide observational real-world study (n=635, 14 sites, MAIC analysis)
- Category
- novel_therapeutics
- Maturity
- Validated
- Journal
- BMC Med
Why it surfaced
Largest real-world validation of serplulimab (PD-1 inhibitor)+chemotherapy for SCLC, using MAIC analysis to benchmark against pivotal trial—important for real-world treatment evidence in this aggressive malignancy.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.